RxDoctor Payments Data

Mamta Patel, MD

Retina Specialist · Tampa, FLNPI 1710923768

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,475 of the $6,313 with a category attached, or 70.9%. 15 manufacturers reported payments, led by Mallinckrodt Enterprises LLC at 59.3% of the total. Reporting peaked in 2019 at $4,112 and has fallen 99.6% since, to $17 in 2025.

$6,313in general payments, 2019–2025

Across 82 payments — averaging $76.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Enterprises LLC$4K
  • AbbVie$1K
  • Aerie Pharmaceuticals, Inc.$203
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$186
  • Mallinckrodt Hospital Products Inc.$158
  • Genentech USA, Inc.$133
  • plus $452 from 9 others

What the payments were for

  • Consulting fees$4,47571%
  • Speaking & faculty fees$190%
  • Food & beverage$1,81229%
  • Education$70%

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,313 in reported general payments places this provider in the 60th percentile of 118 retina specialist providers in Florida.

See all retina specialist providers in Florida

Medicare billing

Part B allowed, 2024
$137,662
Medicare patients
208
Services billed
1,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine19$19,519
Alphagan PBrimonidine Tartrate18$6,016
Prednisolone Acetate79$4,941
CombiganBrimonidine Tartrate/Timolol12$3,981
Atropine Sulfate22$1,755
Latanoprost183$1,703
Ketorolac Tromethamine51$1,514
Brimonidine Tartrate55$695
Dorzolamide Hcl27$477
Timolol Maleate35$418
MoxifloxacinMoxifloxacin Hcl12$392
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat30$381
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha12$132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Alphagan P, Combigan$1,436$29,51649 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 118 retina specialist providers in Florida.

Other retina specialist in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →